
1/9/2020
FDA approves enzalutamide (XTANDI) for metastatic castration-sensitive prostate cancer
“At UCA, we continue to drive state of the art care. As a clinical trial site, interested and qualifying patients had the opportunity to participate in the clinical trial which led to the recent FDA […]